Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics has appointed Christy J. Oliger to its board of directors, effective June 7, 2024. Oliger brings over 30 years of experience in the biopharmaceutical industry, having led significant commercial product launches and built highly effective teams. She currently serves on the boards of Karyopharm Therapeutics, Replimune Group, and LAVA Therapeutics, and has past board experience with Sierra Oncology, Reata Pharmaceuticals, and RayzeBio. Oliger’s extensive experience will support Vera's advancement of atacicept for IgAN treatment and its potential commercial launch.
On June 4, 2024, Vera Therapeutics granted inducement awards to five new employees under its 2024 Inducement Plan. These awards include non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units (RSUs) for 14,500 shares. The stock options have an exercise price of $39.47 per share, matching Vera’s closing price on that date. The stock options and RSUs vest over four years with specific conditions attached. These grants were approved by Vera's Compensation Committee in adherence to Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Vera Therapeutics, a late clinical-stage biotechnology company, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference.
The event will occur from June 10-13, 2024, at the Loews Miami Beach Hotel.
CEO Marshall Fordyce, M.D., will present on June 12 at 10:40 AM EDT, and the management team will engage in one-on-one investor meetings.
Vera Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to its drug atacicept for the treatment of Immunoglobulin A Nephropathy (IgAN). This decision is based on data from a Phase 2b ORIGIN trial, showing atacicept's potential to significantly improve kidney function as measured by eGFR over existing treatments. The company plans to release long-term results from this trial later in 2024 and expects Phase 3 trial results in the first half of 2025, which will support its regulatory approval submission.
Vera Therapeutics announced positive results from its Phase 2b ORIGIN trial of atacicept in treating IgA nephropathy (IgAN) at the 61st European Renal Association Congress. Over 72 weeks, atacicept showed stable kidney function, rapid, and sustained improvements in hematuria compared to placebo. The study revealed a 91% retention rate, enhancing the drug's safety profile. Additionally, atacicept led to significant reductions in Gd-IgA1, hematuria, and UPCR in participants. Vera aims to present 96-week data in Q4 2024 and expects Phase 3 enrollment completion by Q3 2024, with primary endpoint data by H1 2025.
Vera Therapeutics, a biotechnology company, shared positive 72-week data from its Phase 2b ORIGIN clinical trial for IgAN. They reported no kidney function loss with atacicept treatment. They anticipate Phase 3 ORIGIN 3 trial results in 2025. The company completed a $287.5 million financing, strengthening its financial position.
Vera Therapeutics, Inc. (Nasdaq: VERA) granted inducement awards to new employees under its 2024 Inducement Plan. The awards include non-qualified stock options and restricted stock units. The stock options have exercise prices based on Vera's closing trading prices on specific dates. The awards vest over four years, contingent on the employees' continued service with the company. These awards were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Summary not available.
Summary not available.
Summary not available.